Pfizer Strengthens its Obesity Business with the Ecnoglutide Drug

In a calculated bid to capture a lucrative share of the booming global weight-loss market, Pfizer has secured exclusive commercialization rights in mainland China for ecnoglutide, a promising GLP-1 therapy developed by Hangzhou Sciwind Biosciences. The agreement, valued at up to $495 million including upfront and milestone payments, grants Pfizer commercial control while Sciwind retains research, manufacturing, and marketing authorization responsibilities.

Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist, was approved by Chinese regulators in January under the brand name Xianyida to treat type 2 diabetes. The drug is also currently under regulatory review for adult chronic weight management. In late-stage clinical trials, the once-weekly injectable helped Chinese patients achieve a 15.1% placebo-adjusted weight loss, demonstrating efficacy on par with established market leaders like Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

This strategic partnership underscores Pfizer's urgent push to rebuild its revenue growth following a decline in COVID-19 vaccine demand and increasing competitive pressures. After scrapping its own internal GLP-1 pipeline last August due to clinical setbacks, Pfizer aggressively pivoted its strategy toward major acquisitions. The Sciwind partnership follows a recent $10 billion buyout of obesity biotech Metsera and a $150 million upfront licensing agreement with Yao Pharma, a Shanghai Fosun Pharmaceutical subsidiary.

The commercial opportunity in China is substantial, with obesity currently affecting 14.1% of Chinese adults. The demographic trend has even prompted prioritization under the government's "Healthy China" campaign. Pfizer CEO Albert Bourla recently expressed strong confidence in the consumer-driven nature of this space, comparing the massive out-of-pocket potential of the weight-loss market to the explosive historical success of Viagra.

With international heavyweights and domestic biotechs already battling for market share, Pfizer’s latest investment solidifies its ambition to become a leading force in the next generation of chronic weight management therapies.

---

🔖 Sources

Amid obesity push, Pfizer strikes deal worth up to $495M to market Sciwind's approved GLP-1 in China

Pfizer continues obesity buildout with China-focused Sciwind deal

Pfizer Secures $495 Million China Obesity Drug Deal

---

Keywords: Ecnoglutide Drug

Ecnoglutide Drug

---